PALLIATION OF MALIGNANT INTESTINAL-OBSTRUCTION USING OCTREOTIDE

被引：63

作者：

KHOO, D

HALL, E

MOTSON, R

RILEY, J

DENMAN, K

WAXMAN, J

机构：

[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,LONDON W12 0NN,ENGLAND

[2] COLCHESTER GEN HOSP,COLCHESTER CO4 5JL,ESSEX,ENGLAND

[3] ST HELENA HOSPICE,COLCHESTER CO4 4JU,ESSEX,ENGLAND

[4] PRINCESS ALICE HOSP,SURREY,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER | 1994年 / 30A卷 / 01期

关键词：

D O I：

10.1016/S0959-8049(05)80012-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vomiting due to malignant intestinal obstruction is an unpleasant terminal event in many cancer patients, which responds poorly to conventional therapies. Somatostatin and its long-acting analogues reduce intestinal secretion. For this reason, octreotide was used in a phase I/II study of patients with intractable vomiting secondary to intestinal obstruction due to malignant disease. Vomiting was controlled or the volume of nasogastric aspirate was markedly reduced in 18 of 24 (75%) patients receiving a subcutaneous infusion of octreotide (median initial dose 300, range 100-600 mu g/day) for a median of 9.4 (range 1-38) days. A further 2 patients had partial relief of their symptoms. Octreotide is an effective treatment of nausea and vomiting due to malignant bowel obstruction.

引用

页码：28 / 30

页数：3

共 7 条

[1]

ANTHONE GJ, 1990, SURGERY, V108, P1136

[2]

BAINES M, 1985, LANCET, V2, P990

[3]

DHARMSATHAPHORN K, 1980, GASTROENTEROLOGY, V78, P1559

[4] CONTROL OF EMESIS IN BOWEL OBSTRUCTION IN TERMINALLY ILL PATIENTS [J].